Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YMN-136 Vaccine in Advanced Hepatobiliary and Pancreatic Malignancies
NCT07763301Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YMN-136 in liver cancer, pancreatic cancer (PC) and biliary tract cancer (BTC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of Treatment-Related Adverse Events at 24 months. Started Aug 2026; status: recruiting.
02
Drugs
YMN-136
03
Conditions
liver cancerpancreatic cancer (PC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07763301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07763301.